Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy. Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroidresistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile. Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of nonatopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.